Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-19
DOI
10.3389/fimmu.2021.754436
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Photothermal therapies to improve immune checkpoint blockade for cancer
- (2021) Preethi B. Balakrishnan et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- (2021) Jiali Yu et al. NATURE MEDICINE
- Oncolytic herpes simplex virus HF10 (canerpaturev, C‐REV ) promotes accumulation of CD8 + PD ‐1 ‐ tumor‐infiltrating T cells in PD‐L1 – enriched tumor microenvironment
- (2021) Ibrahim Ragab Eissa et al. INTERNATIONAL JOURNAL OF CANCER
- Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
- (2021) Claire Lhuillier et al. JOURNAL OF CLINICAL INVESTIGATION
- Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer
- (2021) Anna Wilkins et al. Journal for ImmunoTherapy of Cancer
- Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
- (2021) Shuguang Zuo et al. EBioMedicine
- Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
- (2021) Hai-Jun Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
- (2021) Josep Malvehy et al. Journal for ImmunoTherapy of Cancer
- Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
- (2021) Bo Zhang et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
- (2021) Rom Leidner et al. Journal for ImmunoTherapy of Cancer
- An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy
- (2021) Zhenrui Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.
- (2021) Carlo Guerrero et al. JOURNAL OF CLINICAL ONCOLOGY
- TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
- (2021) Karen O. Dixon et al. NATURE
- Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
- (2021) Nicolas Jacquelot et al. NATURE IMMUNOLOGY
- Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
- (2021) Danielle M. Lussier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
- (2020) Romualdo Barroso-Sousa et al. Clinical Breast Cancer
- Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma
- (2020) Changqing Xie et al. CLINICAL CANCER RESEARCH
- Combination therapy with oncolytic viruses and immune checkpoint inhibitors
- (2020) Matthew Chiu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
- (2020) Benjamin Leon Musher et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
- (2020) Caroline E. Porter et al. MOLECULAR THERAPY
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
- (2020) Rachael M. Zemek et al. Frontiers in Immunology
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- (2020) Laura Strauss et al. Science Immunology
- Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
- (2020) Sarah Knispel et al. Journal for ImmunoTherapy of Cancer
- ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- (2020) Hailong Sheng et al. Journal for ImmunoTherapy of Cancer
- Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
- (2020) Kevin J Harrington et al. CLINICAL CANCER RESEARCH
- The old CEACAMs find their new role in tumor immunotherapy
- (2020) Zi-Wen Han et al. INVESTIGATIONAL NEW DRUGS
- Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
- (2020) Anna Lucia Tornesello et al. MOLECULES
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
- (2020) Florent Peyraud et al. Cancers
- 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
- (2020) C. Haymaker et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Strengthening the sting of immunotherapy
- (2020) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Oncolytic reovirus-mediated recruitment of early innate immune response reverses immunotherapy-resistance in prostate tumours by inducing a T-cell inflamed microenvironment
- (2020) Nicola E. Annels et al. Molecular Therapy-Oncolytics
- Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
- (2020) Celine Boutros et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
- (2020) James Welsh et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
- (2020) June Kyu Hwang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
- (2020) Karam Khaddour et al. Oncotarget
- Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma
- (2020) Liming Zhang et al. MOLECULAR THERAPY
- The Antiviral Apparatus: STING and Oncolytic Virus Restriction
- (2019) Joel Lee et al. Molecular Therapy-Oncolytics
- Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo
- (2019) Nora Francini et al. BIOCONJUGATE CHEMISTRY
- Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.
- (2019) Sanjiv S. Agarwala et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor lysis with LTX-401 creates anticancer immunity
- (2019) Wei Xie et al. OncoImmunology
- Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21
- (2019) Nicola E Annels et al. CLINICAL CANCER RESEARCH
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- (2019) Vivek Verma et al. NATURE IMMUNOLOGY
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
- (2019) Rachael M. Zemek et al. Science Translational Medicine
- Boiling Histotripsy-induced Partial Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
- (2019) Ki Joo Pahk et al. Scientific Reports
- Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
- (2019) Claire Lhuillier et al. Genome Medicine
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
- (2019) Yonghui Zhang et al. MOLECULAR THERAPY
- Immuno-oncology drug development goes global
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
- (2019) Suzanne Thomas et al. Journal for ImmunoTherapy of Cancer
- 1365PFinal results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment
- (2019) K Yokota et al. ANNALS OF ONCOLOGY
- A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
- (2019) Alice Y. Ho et al. CANCER
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
- (2019) Gayathri Vijayakumar et al. EBioMedicine
- Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer
- (2018) Andrew J Rech et al. CANCER RESEARCH
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma
- (2018) Dipongkor Saha et al. Immunotherapy
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model
- (2018) Hao Liu et al. PLoS One
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- (2018) Charlotte E. Ariyan et al. Cancer Immunology Research
- Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model
- (2018) J. Zhu et al. Diagnostic and Interventional Imaging
- Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
- (2018) Ahmed Mostafa et al. Cancers
- STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
- (2018) Abdi Ghaffari et al. BRITISH JOURNAL OF CANCER
- Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.
- (2018) Jeremy Force et al. JOURNAL OF CLINICAL ONCOLOGY
- The anticancer peptide RT53 induces immunogenic cell death
- (2018) Ewa Pasquereau-Kotula et al. PLoS One
- LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
- (2018) K J Harrington et al. ANNALS OF ONCOLOGY
- Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade
- (2018) Hong Jae Chon et al. CLINICAL CANCER RESEARCH
- Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
- (2018) Mathieu Césaire et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
- (2017) Amanda Rosewell Shaw et al. MOLECULAR THERAPY
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
- (2017) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphatidylserine: A cancer cell targeting biomarker
- (2017) Bhupender Sharma et al. SEMINARS IN CANCER BIOLOGY
- Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
- (2017) Manisha Singh et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
- (2017) Casey R. Ager et al. Cancer Immunology Research
- Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
- (2017) Nils-Petter Rudqvist et al. Cancer Immunology Research
- Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
- (2016) M. E. Rodriguez-Ruiz et al. CANCER RESEARCH
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
- (2016) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor
- (2016) L. Shi et al. CLINICAL CANCER RESEARCH
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
- (2016) E Ilett et al. GENE THERAPY
- 516. A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses
- (2016) Jessica Wenthe et al. MOLECULAR THERAPY
- Viral DNA Sensors IFI16 and Cyclic GMP-AMP Synthase Possess Distinct Functions in Regulating Viral Gene Expression, Immune Defenses, and Apoptotic Responses during Herpesvirus Infection
- (2016) Benjamin A. Diner et al. mBio
- Sensing of HSV-1 by the cGAS–STING pathway in microglia orchestrates antiviral defence in the CNS
- (2016) Line S. Reinert et al. Nature Communications
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
- (2016) E. Moore et al. Cancer Immunology Research
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
- (2016) Patricia Kleinpeter et al. OncoImmunology
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
- (2015) Thomas F. Gajewski SEMINARS IN ONCOLOGY
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
- (2015) Sofia R. Gameiro et al. Oncotarget
- Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
- (2014) Ketil André Camilio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
- (2014) S. Matsumura et al. JOURNAL OF IMMUNOLOGY
- Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells
- (2014) Lorenz Kulzer et al. Journal of Immunotoxicology
- PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma
- (2014) Carmela Passaro et al. Molecular Oncology
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
- (2014) Encouse B Golden et al. OncoImmunology
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- Cytosolic Sensing of Viruses
- (2013) Delphine Goubau et al. IMMUNITY
- Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer
- (2013) Daniel W. Vermeer et al. INTERNATIONAL JOURNAL OF CANCER
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy
- (2013) Yuting Ma et al. OncoImmunology
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
- (2012) Maria Grazia Ruocco et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
- (2012) Koji Kono et al. OncoImmunology
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The DNA Damage Response Induces IFN
- (2011) Sabrina Brzostek-Racine et al. JOURNAL OF IMMUNOLOGY
- Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation
- (2010) Fabian Benencia et al. CANCER BIOLOGY & THERAPY
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
- (2009) François Ghiringhelli et al. NATURE MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started